Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 17Terminated 4Active not recruiting 3Unknown 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 67Thoracic 48Breast 13Genitourinary 9Tumor-Agnostic 6Gynecologic 5Other solid neoplasm 2Lymphoid 2CNS 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1

Conditions

Mesothelioma 1Advanced Solid Tumor 1

Interventions

Injections 54pembrolizumab 39Carboplatin 20Bevacizumab 19Cyclophosphamide 18toripalimab 15tislelizumab 14fludarabine 14Nivolumab 14Cisplatin 14Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Cetuximab 11Fluorouracil 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × durvalumab × Other solid neoplasm × Clear all
NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Inimmune Corporation

Phase 1 Recruiting
50 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Baylor College of Medicine

Phase 1/2 Recruiting
52 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡